Sequential JAK inhibition enhances antitumor immunity after combined anti–PD-1 and anti-CTLA4
Marcel Arias-Badia(University of California, San Francisco), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Rachel Wolters(University of California, San Francisco), Jacob V. Gorman(AbbVie (United States)), Aram Lyu(Fred Hutch Cancer Center), Wendy Ritacco(AbbVie (United States)), Zenghua Fan(University of California, San Francisco), Peixi Chen(University of California, San Francisco), Fiona Harding, Serena S. Kwek(University of California, San Francisco), Aahir Srinath(University of California, San Francisco), Matthew D. Clark(City College of San Francisco), Andrew Goodearl(AbbVie (United States)), Averey Lea(University of California, San Francisco), Yee May Lwin(University of California, San Francisco), Ali Setayesh(University of California, San Francisco), Diamond Luong(University of California, San Francisco)
Cited by 4
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|Annals of Oncology|2019|484
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
|Cell|2023|410
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
|Prostate Cancer and Prostatic Diseases|2021|224
Identification and Testing of Superior Reference Genes for a Starting Pool of Transcript Normalization in Arabidopsis
|Plant and Cell Physiology|2010|219